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Supplemental methods
Deep-targeted sequencing
Peripheral blood mononuclear cells (PBMC) were isolated from fresh EDTA blood with Lymfoprep (Axis-Shield, Oslo, Norway). Genomic DNA was extracted using QIAamp DNA Blood Midi kit (Qiagen, Hilden, Germany) and quantified on a Qubit® 2.0 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). The SU-DHL4 cell line was cultured in 90% RPMI 1640 media, 19% FCS, and 1% streptomycin at 37°C. Primers were designed to flank TP53 exons 2-10 (RefSeq NM_00546.5) including splicing sites with 2 bp intronic overlap. We used one primer-pair for exons 2, 3, 7, 8, and 10, two primer-pairs for exon 5 and 9, while exon 4 was covered using 4 primerpairs. Patient samples were amplified using Phusion® Hot Start II High-Fidelity DNA polymerase (Thermo Fisher Scientific) with 30 cycles of PCR. Library preparation was performed on a SciClone G3 Liquid Handling Workstation (Perkin Elmer, Waltham, MA, USA) according to the manufacturer's protocol: KAPA DNA Library Preparation, Rev 1 (Roche Nimblegen, Madison, WI, USA). In brief, amplicons were purified using SeqCap Pure Capture Bead Kit containing AMPure® XP Beads (Beckman, Brea, CA, USA). Following end repair and poly(A)-tailing, adaptor ligation was performed with SeqCap Adapter Kit A and B (Roche NimbleGen) or NEXTflex™ DNA Barcodes 96 (Bioo Scientific, Austin, TX, USA). Following seven cycles of PCR and an additional AMPure step, libraries were pooled either 24 or 96 samples per lane and sequenced as paired-end on a HiSeq2500. Using HiSeq® SBS Kit v4 (2x125 base PE; Illumina, San Diego, CA, US), 75% of reads in the target region were paired.
Determination of sensitivity of the assay
To establish the sensitivity of the TP53 mutation assay, serial dilution of Sanger validated TP53 mutations (TP53muts) were sequenced. Pilot study samples were handled as described above using only SeqCap Adapters (Roche NimbleGen) and sequenced as paired-end on a MiSeq using MiSeq Reagent Kit v2 (Illumina, 2x250 base PE). With mutations detected as low as 0.023% variant allele frequency (VAF), the limit of detection (LOD) was established at 0.2% VAF while a dilution step (dilution factor 5) was included to increase the robustness of the assay ( Figure S2A ). By subtraction of the VAF from variants called in pure cell line DNA, the correlation between dilution grade and detected VAF was improved (r 2 > 0.9957 vs r 2 > 0.9967, squared Pearson's correlation coefficient). Thus, this approach was chosen for future analyses, replacing any negative adjusted VAF with zero. The range of the dilution step and the ability to detect insertions and deletions (indels) was confirmed based on similar serial dilution of patient samples with known TP53 indels ( Figure S2B ). Finally, the performance of the assay was evaluated assessing eight del(17p) samples with unknown TP53 mutational status. As expected, seven of eight samples harbored TP53 mutations (Table S1 ).
Bioinformatic workflow
Based on the pilot studies, a workflow for detection of low burden variants was developed in CLC Biomedical Genomics Workbench 3.0 (CLC BGW, Qiagen). Paired reads were trimmed 20 bp 5` to remove primers and 1 bp 3` to remove bad quality reads further allowing for a quality-score of 0.01. Reads were mapped to the hg19 (ensembl GRCh37.73) reference genome and realigned using 2 multipasses. Directional frequency filter was set to zero to ensure variant calls in unpaired reads (25% of target region). The combined call of both a low frequency (VAF ≥0.001%) and basic variant detection tool (VAF ≥2%) were used to ensure detection of both high and low burden mutations. To describe the distribution of inevitable low frequency errors (error distribution), all variants with a minimum of 1 variant read and VAF ≥0.001% were called.
Dilution match algorithm
In analyses downstream of CLC BGW, the adjusted dilution ratios (aDRs) and the dilution grades (DGs: reference allele frequency of p.Arg273Cys) were plotted and expected to match a line with a slope of one ( Figure S3A ). However, a cluster with aDRs around 1 (i.e. a distance to a line with slope of 1 above 0.5) was also observed and consequently excluded. We next calculated the 99.9% reference range (mean ± 3.27 SD) of remaining distances to a line with a slope of 1 and trimmed the reference range to an absolute distance ≤0.16. Variants within this distance were considered to have a dilution match ( Figure S3B ).
Dilution match algorithm
Stereotypic error model
We further modeled the distribution of stereotypic errors 1 to identify outliers considered as true mutations. 2 As modeling of variant reads included inevitable differences in read depth (coverage), we modeled VAF in two steps as summarized in Figures S4-S6 . First, each unique genomic position including nucleotide change (e.g. g.17:7579472G>C) were grouped and modeled only if observed in 20 samples or more. Secondly, we grouped each unique nucleotide change (e.g. A>T) and modeled only if observed in 20 samples or more. Extreme outliers were excluded from modeling by truncating VAFs that were further than 2 and 4 standard deviations (SDs) from the mean of the log transformed VAF distributions. Subsequently, truncated VAFs were modeled to fit gamma distributions that allowed us to identify outliers using Bonferroni adjusted right-sided Pvalues of 10 -2 , 10 -4 , and 10 -6 . Unfit for modeling, variants with a rare nucleotide change observed in less than 20 samples were called with a LOD of 2% VAF. Due to the design of the dilution match algorithm, c.817C>T (p.Arg273Cys) could not be modeled by this approach. Thus, this mutation was called with a LOD of 2% VAF.
Reporting variant findings
Variants identified by the dilution match algorithm (DMA) and stereotypic error model (SEM) with a minimum of 10 variant reads and a VAF ≥0.2% were called and referenced in the IARC TP53 database (http://p53.iarc.fr) excluding validated polymorphisms, synonymous mutations and mutations predicted to encode functional p53 (Table S5) .
Comparison of results from the DMA and SEM was performed with 2x2 contingency tables using combinations of annotated P-values and SDs for LODs 0.2%, 0.3%, and 1% VAF to evaluate the performance of both methods (Table S3 ). The three LODs represented our threshold, the lower threshold used in previous publications, [2] [3] [4] and the threshold of minor TP53 mutations, 3 respectively.
All analyses downstream of CLC BGW were performed with R version 3.4.1 using packages tidyverse, fitdistrplus, robustHD, epiR, Publish, survival and survminer. 5 Source code is available upon request. 
Validation by droplet digital PCR and capture based NGS
Evaluation of CLL cell fraction by flow cytometry
To evaluate the fraction of CLL cells in purified PBMCs, we reanalyzed the diagnostic fcs files. Samples were originally run on a FACSCalibur or FACSCanto II (BD, Franklin Lakes, NJ, USA). Reanalysis was performed using FlowJo® vX.0.7 (Flowjo, Ashland, OR, USA). The fraction of CLL cells (CD5+, CD19+) was calculated from mononuclear cells gated by CD45 and SSC.
Supplemental results
SEM identified a c.848G>A (p.Arg283His) in 45 patients (range: 0.20-0.43% VAF, Figure S7A ). However, none of these were positive by DMA. This specific mutation was considered low frequent noise and excluded from downstream analyses comparing DMA and SEM. Four variants were only detected by DMA including three c.848_849delGC (p.Arg283fs*22) positioned at a problematic position with a wide distribution of background noise ( Figure S7 A-B ) and one c.488A>G (p.Tyr163Cys) that was validated by ddPCR but excluded based on SEM modeled on only 24 events ( Figure S7C ). Twenty-two variants were only detected by SEM. This included one c.338T>G (p.Phe113Cys) identified at 0.6% VAF, while the remaining 21 variants fell below 0.3% VAF (Table S4) ; the LOD applied in previous studies. 2, 4 All 70 true negative variants with VAF ≥1% excluded by both the SEM and the DMA consisted of a splicing site variant c.74+2T>G. This variant showed a multimodal distribution considered unfit for modeling and is thought to be a mapping error rather than a result of PCR ( Figure S7D ).
Due to redundant mutations, validation of the initial 20 TP53muts by ddPCR included 30 low burden TP53mut (VAF ≤10%) with a median VAF of 0.91% (IQR: 0.41-2.95%). All tested samples were validated (Table S6 ). In addition, three high burden TP53muts (VAF >10%) and two minor TP53muts (VAF <1%) called with a LOD of 0.1% VAF were also validated. Among TP53muts above 1% VAF tested by capture based targeted NGS, 24 (92%) were validated: 2 mutations could not be validated (VAF of 1.2% and 2.9%, Table S4 ). Table S1 . Analysis of 8 del(17p) test samples with unknown TP53 status. Nine TP53 mutations were identified in the 7 of the 8 samples using the dilution match algorithm. Dilution grade (DG) and dilution ratio (DR) were highly similar with short distances from a slope of one (DFSO = DG -DR). Table S2 . The primers used for PCR amplification of TP53 exons 2-10. Table S3 . Contingency tables show results for the entire study cohort (n=308) of the dilution match algorithm (DMA) and stereotypic error modeling (SEM) at three different limits of detection (LOD of VAF ≥0.2%, VAF ≥0.3%, and VAF ≥1%) and 6 different SEM settings (P-values and SD). Standard deviations (SD) were used for truncating extreme outliers before modeling and Bonferroni adjusted P-values were used to identify modeled outliers. Table S6 . Validation by droplet digital PCR. Probes for initial TP53 findings validated all 33 tested mutations above the limit of detection (LOD) of the assay (0.2% VAF). Two mutations below the LOD were also validated, but not included in the final report. Note that 14 mutations in 7 nondiagnostic patients, who were neither sampled 0-200 days before treatment were also tested and validated. Table S8 . Patient characteristics at time of treatment stratified according to TP53 (A) and IGHV mutational status (B). TP53 wild-type (TP53wt), TP53 mutation without del(17p) (TP53mut), del(17p) regardless of TP53 mutational status (Del(17p)), beta-2-microglobulin (B2M), fluorescent in situ hybridization (FISH). Figure S2 . Figure S5 . 
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